



ASX Announcement

FOR IMMEDIATE RELEASE

SIR-SPHERES® PUBLIC AND PRIVATE HEALTH FUND REIMBURSEMENT

SYDNEY, Australia, 9th March 2006: Australian medical technology company, Sirtex Medical Limited (ASX: SRX) announced today that Private Health Fund reimbursement for SIR-Spheres microspheres has been approved and will be effective immediately.

SIR-Spheres microspheres are used for the treatment of non-resectable liver cancer.

Private health funding is provided through the Prosthesis Benefit listing. Under the new private benefit reimbursement arrangements, the cost of SIR-Spheres will be \$8,014.00. Private healthcare patients will have to pay a gap of \$792.00.

As previously announced by the Company on 22 December 2005, the Australian Government approved public funding for the treatment of non-resectable liver tumours on an interim basis. Sirtex today announces that this public funding will be effective May 2006 when the new MBS schedules will be published and will include additional MBS numbers for Radiology and Nuclear Medicine. This funding will be for the treatment of secondary liver cancer from colorectal cancer (CRC) in combination with 5FU/LV.

Sirtex Medical Ltd is an international company, located in Australia, the United States and Germany. Sirtex Medical Ltd aims to become the world leader in liver cancer treatment products. The Company believes the unmet demand for effective treatment of liver cancer provides an opportunity for Sirtex products.

For more information, visit our website at www.sirtex.com.

A handwritten signature in dark ink, appearing to read "AL", with a horizontal line above it.

**ANGELA LEARD
COMPANY SECRETARY**

#####

Contact: Gilman Wong
 CEO
 +61-2-9936-1400